Treatment results of the thioether lipid ilmofosine in patients with malignant tumours.
In a multicentre study patients with liver metastases stratified to the histology of the primary tumour were investigated. A total of 102 patients with colorectal adenocarcinoma, non-small-cell lung cancer, pancreatic cancer, primary liver carcinoma and malignant melanoma were treated with the thioether lipid ilmofosine. The drug was administered orally as a tablet at a dosage of 150-300 mg/day (75 mg/tablet). The tolerability of ilmofosine was poor. There was a dose-limiting gastrointestinal toxicity with nausea, vomiting and loss of appetite (WHO grade II-IV) in 67% of patients. During the period of therapy (1-29 weeks, 8.5 weeks mean) no complete remission and no partial response were observed. We thus conclude that treatment with oral ilmofosine is not effective in patients with liver metastases due to various malignancies.
Winkelmann
M
M
Medizinische Klinik und Poliklinik, Heinrich-Heine-Universität Düsseldorf, Federal Republic of Germany.
Ebeling
K
K
Strohmeyer
G
G
Hottenrott
G
G
Mechl
Z
Z
Berges
W
W
Scholten
T
T
Westerhausen
M
M
Schlimok
G
G
Sterz
R
R
D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D015179:Colorectal Neoplasms / Q000188:drug therapy; D004341:Drug Evaluation; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008175:Lung Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D010742:Phospholipid Ethers / Q000627:therapeutic use* / Q000633:toxicity*
D000970:Antineoplastic Agents; D010742:Phospholipid Ethers; C043297:ilmofosine